- Home
- ADPT vs MSEX Comparison
ADPT vs MSEX Comparison
Compare ADPT & MSEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- MSEX
- Stock Information
- Founded
- ADPT 2009
- MSEX 1897
- Country
- ADPT United States
- MSEX United States
- Employees
- ADPT N/A
- MSEX N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- MSEX Water Supply
- Sector
- ADPT Health Care
- MSEX Utilities
- Exchange
- ADPT Nasdaq
- MSEX Nasdaq
- Market Cap
- ADPT 1.1B
- MSEX 895.1M
- IPO Year
- ADPT 2019
- MSEX N/A
- Fundamental
- Price
- ADPT $7.33
- MSEX $62.66
- Analyst Decision
- ADPT Strong Buy
- MSEX Hold
- Analyst Count
- ADPT 5
- MSEX 4
- Target Price
- ADPT $9.40
- MSEX $59.33
- AVG Volume (30 Days)
- ADPT 2.4M
- MSEX 247.8K
- Earning Date
- ADPT 05-01-2025
- MSEX 05-07-2025
- Dividend Yield
- ADPT N/A
- MSEX 2.17%
- EPS Growth
- ADPT N/A
- MSEX 39.94
- EPS
- ADPT N/A
- MSEX 2.47
- Revenue
- ADPT $178,957,000.00
- MSEX $191,877,000.00
- Revenue This Year
- ADPT $21.20
- MSEX $10.20
- Revenue Next Year
- ADPT $22.06
- MSEX $6.56
- P/E Ratio
- ADPT N/A
- MSEX $25.39
- Revenue Growth
- ADPT 5.10
- MSEX 15.40
- 52 Week Low
- ADPT $2.28
- MSEX $45.57
- 52 Week High
- ADPT $9.01
- MSEX $70.73
- Technical
- Relative Strength Index (RSI)
- ADPT 43.95
- MSEX 55.51
- Support Level
- ADPT $7.38
- MSEX $59.37
- Resistance Level
- ADPT $8.30
- MSEX $63.97
- Average True Range (ATR)
- ADPT 0.75
- MSEX 2.29
- MACD
- ADPT -0.04
- MSEX -0.32
- Stochastic Oscillator
- ADPT 33.85
- MSEX 42.62
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About MSEX Middlesex Water Company
Middlesex Water Co owns and operates regulated water utility and wastewater systems in the U.S. The firm primarily operates in the eastern states of New Jersey, Delaware, and Pennsylvania. The company has two operating segments, Regulated and Non-Regulated. The regulated business includes collecting and distributing water to residential, commercial, industrial, and fire protection consumers. The non-regulated business includes contract services for the operation of private water and wastewater systems. The majority of the company's revenue is derived from the Regulated segment and from residential customers.